US President, Joe Biden, has urged Americans not to panic about the new COVID-19 Omicron variant and said the United States was making contingency plans with pharmaceutical companies if new vaccines are needed, Reuters news agency reported on Tuesday.
Biden said the country would not go back to lockdowns to stop the spread of the Omicron variant and that he would lay out his strategy on Thursday for combating the pandemic over the winter.
The president said in remarks at the White House following a meeting with his COVID-19 team: "This variant is a cause for concern, not a cause for panic. We're going to fight and beat this new variant."
He also urged people to get vaccinated, get boosters and wear masks adding that it was inevitable that Omicron cases would emerge in the United States.
While Biden said he believed that existing vaccines would continue to protect against severe disease, he added that his administration was working with vaccine makers Pfizer (NYSE:PFE), Moderna (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) to develop contingency plans.
President Biden also said he would direct the US Food and Drug Administration and the Centres for Disease Control and Prevention (CDC) to make those vaccines available quickly.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML